Volume boom, profit stuck — and management won't say when that changes
Revenue jumped 26.5% on inpatient and OPD volume surges, but profit fell 1.1% YoY. Noida's ₹49-crore EBITDA loss (though improving) and cost inflation are swamping expected operating leverage. The market saw through the headline — stock recovered by day 5 but FII sold while DII rotated in.
₹1,304 Cr
+26.5% YoY
₹157 Cr
-1.1% YoY
23.8%
including Noida drag
+28%
YoY growth
On the surface, Medanta's Q1 is a growth story. Revenue hit ₹1,304 crore, up a quarter on inpatient and OPD volume surges. But there's a sleeper in the numbers: net profit slipped 1.1% year-on-year to ₹157 crore despite that headline growth. The gulf between +26.5% revenue and -1.1% profit is the real story of the quarter.
Where the margin went
Noida is both progress and a drag. The ₹49-crore EBITDA loss this quarter is a sharp improvement from the ₹236-crore loss in Q4 — and management trumpets that as ahead of plan. But it is still a loss. Consolidated EBITDA margin sits at 23.8%; excluding Noida, the core business runs 25.8%. The gap between those two numbers is the difference between a margin-expanding story and a margin-pressured one. Management cites cost discipline and "operating leverage as Noida scales," but the data says otherwise: revenue up 26.5%, EBITDA margin actually tightening because of unit drag and cost headwinds (manpower, materials). Until Noida hits breakeven — not just improves, but reaches zero loss — consolidated margin cannot expand materially.
So we have a constant focus on our cost line items, including material cost and manpower cost as well as other cost items. So there is a continuous effort which keeps on going around this.
Noida ahead of internal expectations on financial returns
Noida income ₹86 Cr, EBITDA loss ₹49 Cr (vs. ₹236 Cr loss Q4); volume growth 30-40% QoQ; occupancy 30-40% mid-scale
Supported
Cluster 2 ex-Noida delivered 28% revenue growth and 40% EBITDA growth at 32% margin
Lucknow/Patna revenue +28%, EBITDA +40%, margin 32% confirmed
Supported
EBITDA margin of 25.8% ex-Noida shows strength of core platform
Cluster 2 ex-Noida is 25.8%, but Cluster 1 absorbs all corporate costs; true unit margins opaque
Overstated
PAT of ₹157 Cr shows underlying earnings trajectory remains healthy
PAT ₹157 Cr flat YoY (-1.1%); prior year Q1 FY26 had ₹196 Cr one-time EPCG reversal gain; adjusted YoY growth much lower
Contradicted
No major structural cost headwinds; cost discipline ongoing
ARPOB +5% YoY vs. inpatient volume +28%; suggests case-mix dilution or pricing pressure, not cost advantage
Slightly overstated
What changed on this call
Noida breakeven timeline: Moved forward from H2 FY27 to "earlier than H2 FY27." The ₹49-crore loss this quarter, down sharply from ₹236 crore Q4, supports that trajectory. But management didn't pin down a date — "earlier" still leaves Noida loss-making for at least one more quarter, extending the consolidated margin drag. Guwahati scope doubled, capex nearly doubled: Originally 400 beds, ₹500 crore capex. Now 650 beds, ₹970 crore capex — a ₹470-crore increase. Management credits National Building Code 2026 relaxations (FSI, height) enabling 2x sq ft (6.5L to 9.8L). Procedural capacity doubled (OTs 13-14 to 28-30). Sounds like opportunity, but a 94% capex jump for a 63% bed increase is a yellow flag: ₹1.5 lakh per incremental bed. Other greenfield projects (South Delhi, Varanasi) may face similar cost surprises. Expansion pipeline upgraded: Now 3,350 beds over 3-4 years (vs. prior 2,700). That's 22% more capacity in the roadmap. But the capex per bed is rising — Guwahati ₹1.5L vs. historical norms. If other projects follow this per-bed inflation, the ₹4,850 crore budget could require a reset.
Strong volume growth (+28% inpatient, +34% OPD) across portfolio and geographies
Noida ahead of schedule (₹49 Cr loss vs. ₹236 Cr Q4); path to breakeven clearer
Cluster 2 (Lucknow, Patna) delivering 32% margins and 40% EBITDA growth validates Tier-2 model
Guwahati expansion 650 beds (from 400) unlocks new Tier-2 market with procedural capacity doubling
International patient revenue +23% YoY; OPD pharmacy +51% YoY; revenue diversification working
PAT flat (-1.1%) despite 26.5% revenue growth; no operating leverage visible
Consolidated EBITDA margin 23.8% (Noida drag) vs. core 25.8%; margin contraction despite scale
Gurgaon volume growth 7-10% vs. network 20%+ (ex-Noida); flagship maturity and saturation risk
Capex inflation: Guwahati +₹470 Cr (94% increase) for 63% bed addition; ₹1.5L per bed flags future project risk
Management refuses margin guidance and hedges on margin sustainability; defensive posture
Margin compression unresolved
HighPAT flat (-1.1%) despite 26.5% revenue growth. EBITDA margin 23.8% consolidated. Noida ₹49 Cr loss still dragging. If Noida breakeven slips beyond Q3, margin inflection could be delayed into late FY27 or FY28. This is the crux of the bull thesis — if it stalls, valuation reprices down.
Greenfield capex inflation and execution risk
HighGuwahati capex jumped 94% (₹500→₹970 Cr) for 63% bed addition. If other projects face similar surprises, the ₹4,850 Cr expansion pipeline could balloon. South Delhi, Varanasi still in approval. Execution slips or cost overruns would stretch debt, compress returns, and delay margin inflection further.
Cluster 1 (Gurgaon) saturation and growth deceleration
MediumGurgaon volume growth 7-10% vs. network 20%+ (ex-Noida). At 1,500 beds, 15 years old, near-full occupancy, Gurgaon is the cash cow. If it matures below double-digit growth, the consolidated growth rate will moderate below 20%+ and depend increasingly on Noida and Cluster 2 — both still ramp-up/unproven at scale.
Noida timing slippage beyond H2 FY27
MediumNoida is still losing ₹49 Cr EBITDA this quarter. "Earlier than H2 FY27" is vague and suggests breakeven could be anywhere Q2-Q4 FY27. If occupancy growth slows (currently 30-40%, not yet robust) or costs rise, breakeven could slip to Q1 FY28. Each quarter of delay extends the margin headwind.
Pricing pressure and case-mix dilution
MediumARPOB up only +5% YoY despite inpatient volume +28%. This is a misalignment: strong volumes but muted ARPOB growth suggests pricing pressure or case-mix shift toward lower-ARPOB procedures. If Lucknow/Patna growth moderates and pricing softens, 32% Cluster 2 margins may not be sustainable — exposing margin upside as a mirage.
How the street is positioned
The market's own verdict is measured: wait and see. The stock fell 0.76% on day 1 post-result, then recovered to +1.97% by day 5. That pop-and-fade is instructive — investors initially sold the revenue headline as soon as profit momentum stalled, but value hunters found support. Price at ₹1,422.60 sits above its 20-day (₹1,408.66), 50-day (₹1,339.13), and 200-day (₹1,201.31) averages, technically supported. But it is 4.6% below its all-time high of ₹1,491, signaling the market has already marked down the growth story for margin uncertainty. Ownership is rotating. FII trimmed by 0.69 percentage points to 9.46% (Q1 FY27 vs. 10.15% Q4 FY26), while DII added 2.13 percentage points to 16.89% (from 14.76%). That is classic institutional rotation: offshore buyers stepping back, domestic institutions rotating in at the new risk-adjusted valuation. HDFC Mutual Fund's May bulk buy of 10 lakh shares at ₹1,225 (now up 16%) signals long-term conviction, but FII selling is a yellow flag — offshore investors are not convinced margin inflection is imminent, and are taking some profits or rotating to cheaper franchises.
1 · Noida EBITDA breakeven (not just loss reduction)
Target Q2-Q3 FY27. The metric: EBITDA loss must reach zero, not just improve. This is the linchpin of the margin story. If Noida achieves breakeven on schedule (vague as "earlier than H2" is), consolidated margin will inflect upward. If slips into Q4 or beyond, the bull case stalls.
2 · Gurgaon OT activation and cath lab ramp
Target Q2 onwards (target: 44-45 OTs total). Metric: Q2 Gurgaon EBITDA growth. Currently +13% EBITDA on +10% revenue. If procedural additions drive EBITDA toward +20%+ growth, it signals pricing power and mix shift. If flat, it confirms Gurgaon saturation — a major headwind for consolidated growth.
3 · Cluster 2 margin sustainability (Lucknow, Patna)
Target Q2-Q3 FY27. Metric: ex-Noida Cluster 2 EBITDA margin. Now 32% — management concedes this is "exceptional, not normal." As units scale, do margins hold above 30% or compress below 28%? If sustained at 30%+, the long-term case holds. If drops to 27-28%, growth without margin is a treadmill.
4 · Capex tracking vs. ₹800-900 Cr FY27 guidance
Target Q2-Q3 FY27. Q1 capex ₹161 Cr (annualized ~₹640 Cr). If run rate jumps to ₹900+ Cr, Guwahati cost inflation may be harbinger of a broader reset. Every ₹100 Cr capex increase = ₹7-10 Cr added interest cost at 7-8% borrowing rates — P&L impact that will drag FY27 PAT further.
Medanta is not broken, but it is not yet proven either. The volume story is solid — inpatient +28%, OPD +34%, Cluster 2 geography paying off. Noida is ahead of schedule, Guwahati is expanding, and the clinical franchise is real. But the profit story lags the revenue story, and management's refusal to guide on margins leaves the biggest question unanswered: when does scale deliver margin expansion? Until Q2 proves margin inflection, the stock is fairly valued as a growth-at-moderate-margin play.
The honest read: this is a steady execution story, not a step-change. The company is doing what it said (Noida ramp, Cluster 2 growth, capacity additions), but in an environment of cost inflation and pricing pressure. The profit inflection, if it comes, is likely Q3-Q4 FY27, not imminent. The number to track from here is consolidated EBITDA margin — not the headline PAT, but the true operating margin. If it stays below 24%, the operating leverage story stalls. If it hits 26% by Q3, the bull case accelerates. Until then, hold for the journey, but do not chase the headline.
Strong volume growth masks margin pressure; Noida ahead of plan
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Met Noida ramp-up guidance; missed margin inflection. Avoided specific earnings guidance this quarter.
Neutral
next 1–2 quarters
Optimistic
multi-year
Medanta delivered 26.5% revenue growth and a strong Noida ramp-up (EBITDA loss ₹49Cr, down from ₹236Cr), validating the greenfield strategy. However, PAT contracted 1.1% despite robust top-line growth, signaling margin compression—a material miss vs. expected operating leverage. Long-term, the 3,350-bed expansion pipeline and Cluster 2's 32% margins are compelling, but execution risk on capex (Guwahati cost inflation) and near-term profitability headwinds warrant a cautious stance.
₹1304.1 Cr
Revenue · +26.5% YoY₹157.3 Cr
Reported PAT · −1.1% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Strong growth driven by robust patient volumes and Noida scale-up
METInpatient +28%, OPD +34% YoY; Noida EBITDA loss fell ₹236Cr to ₹49Cr QoQ
Cluster 2 ex-Noida delivered 28% revenue growth and 40% EBITDA growth
METCluster 2 confirmed 28% revenue +40% EBITDA, 32% margins reported
EBITDA margin of 25.8% ex-Noida shows strength of core platform
OVERSTATEDReported EBITDA margin 23.8% including Noida drag; ex-Noida 25.8% but Cluster 1 absorbs all corporate costs
PAT of ₹157.3 Cr shows underlying earnings trajectory remains healthy
MISSPAT ₹157.3 Cr flat YoY (-1.1%) despite revenue +26.5%; prior year included ₹196 Cr one-time gain
Noida ahead of internal expectations on financial returns
METNoida income ₹855m (vs ₹525m Q4), EBITDA loss ₹49m (vs ₹236m loss Q4); target was H2 FY27 breakeven
Earnings quality
What changed since the last call
Noida breakeven target brought forward
UpgradePrior: H2 FY27. Now: Expected earlier than H2 based on Q1 ₹49Cr EBITDA loss vs ₹236Cr in Q4.
Guwahati scope and capex expanded
Upgrade400 beds → 650 beds; capex ₹500Cr → ₹970Cr. Building Code 2026 allowed 6.5L → 9.8L sq ft; OTs doubled 13-14 → 28-30.
Expansion pipeline quantified upward
UpgradePrior: 2,700 beds over 3-4 years. Now: 3,350 beds. But capex inflation evident (Guwahati ₹1.5L per incremental bed).
CGHS rate hike benefit minimal
DowngradeOctober 2025 hike fully in Q1, but CGHS = 10-12% of revenue; no material P&L move disclosed.
Cluster 1 (Gurgaon) growth slowing vs Cluster 2
DowngradeVolume growth 7-10% in 1,500-bed Gurgaon vs 20%+ in Lucknow/Patna; structural maturity risk.
The Q&A
Analysts pressed hard on margin guidance (Parth Sodha), capex per bed (Vivek), and whether Cluster 2 can sustain 30% margins (Raman KV). Management deflected on margins, citing corporate cost allocation; acknowledged Lucknow's growth is 'exceptional, not normal'; hedged on future guidance. Some evasion on specialty mix pressure (oncology share fell 70bps YoY despite growth). Overall: analysts skeptical, management confident but non-committal on key metrics.
Execution priorities vs demand — Sucrit Patil, Eyesight Fintrade
PartialFocus on clinical quality, Noida ramp-up, adding doctor capacity, technology (LINAC, robot, cath labs). No major competitive pressure cited; emphasized 'flight to quality' tailwind.
Margin guidance outlook — Parth Sodha, Trinetra Asset Managers
PartialWe don't give margin guidance. Already at 24% reported, 26% ex-Noida. Operating leverage as Noida matures, no structural cost headwinds foreseen.
Capex allocation & timeline — Abdulkader Puranwala, ICICI Securities
AnsweredINR4,850 Cr is future requirement. Q1 capex INR161 Cr. Already have approvals for Guwahati; policy changes welcome but not essential.
Oncology specialty mix decline — Abdulkader Puranwala, ICICI Securities
DodgedNo. Actually increased 13.7% to 14.4%. Kidney/urology up 7.6% to 8.2%. Reporting methodology differs; 'pie of a hundred'—other specialties growing faster.
Noida occupancy and specialty ramp — Amey Chalke, JM Financial
AnsweredOccupancy 30-40% but not material metric due to ongoing bed additions. All major specialties operational except liver transplant. No significant capex planned; 14 OTs, latest equipment already in place.
Gurgaon vs Lucknow growth comparison — Vivek, Emkay Global
AnsweredNot comparable. Gurgaon: 1,500 beds, 15 years old, ~full capacity. Lucknow: ~750 beds, 5-6 years old, 100M+ population base. Lucknow growth is 'exceptional, not normal'. Gurgaon double-digit volume growth despite scale is itself a feat.
Guwahati capex inflation — Vivek, Emkay Global
AnsweredNational Building Code 2026 changes allowed 2x sq ft (30-40K to 60K); floor plate 6.5L to 9.8L sq ft. Doubled OTs (13-14 to 28-30), cath labs, LINACs. Not bed-driven, procedure-driven.
CGHS rate hike impact — Vivek, Emkay Global
AnsweredFully baked into Q1 (April-June). CGHS only 10-12% of revenue, not moving needle. Long-overdue hike (since 2017) but modest impact on overall P&L.
Cluster 1 vs Cluster 2 growth differential — Raman KV, Sequent Investments
PartialNot slowdown, relative growth. Cluster 1: Ranchi 100-bed facility added, Indore 80-bed acquisition coming Q2/Q3 (cancer focus). Gurgaon: activating 2 more OTs (total 44-45), adding cath labs. Brownfield mix of beds + procedural capacity.
Cluster 2 margin sustainability — Raman KV, Sequent Investments
PartialNo margin guidance. Cluster 1 absorbs all corporate costs, so Cluster 2 inflated. Newer units have lower R&M, legacy costs. No structural difference in work. Noida benefits from operating leverage as it scales.
Guidance
No explicit FY27 revenue guidance given
LowManagement silent on annual target. Q1 +26.5% YoY sets floor; Cluster 2 momentum suggests 20%+ system growth sustainable.
No margin guidance; 'already at 24% reported, 26% ex-Noida'
LowManagement refuses to commit to margin expansion despite operating leverage expected from Noida. Defensive posture.
FY27 capex implied ₹6,400+ Cr; future pipeline ₹4,850 Cr for 3,350 beds
MediumQ1 capex ₹161 Cr; annualized ~₹640 Cr on track. Guwahati ₹970 Cr largest project; others (South Delhi, Varanasi, Guwahati) in design/approval.
Risks the call surfaced
Profitability compression
HighRevenue +26.5% but PAT -1.1%. EBITDA ex-Noida 25.8% suggests core margins flat. Cost inflation (manpower, materials, fuel) may be offsetting volume upside.
Greenfield execution risk
HighGuwahati capex jumped ₹500 Cr → ₹970 Cr for 650 beds (vs 400 beds originally). Building Code 2026 enabled but signals cost surprises. South Delhi, Varanasi projects still in approval stage.
Cluster 1 (Gurgaon) maturity
MediumGurgaon (1,500 beds, 15 years old, near-full occupancy) growing only 7-10% volume despite Medanta network momentum. Indicates market saturation or competitive share loss.
Noida breakeven timing
MediumNoida still losing ₹49 Cr EBITDA this quarter (vs ₹236 Cr Q4). While improving, profit-neutral status still quarters away. Risk of further cost overruns or demand slower than projected.
Competitive intensity
MediumManagement cites 'flight to quality' but doesn't acknowledge direct competitor threat. ARPOB growth only +5% despite volume +28%—suggests either case mix dilution or pricing pressure. Lucknow/Patna growth is 'exceptional, not normal'.
Management
Score 6/10. Candid on operational metrics (volumes, occupancy, ARPOB) but evasive on margin trajectory and guidance. Avoided 'margin guidance' question repeatedly despite being asked 3+ times. Transparent on one-time items. Delivery on Noida ramp-up ahead of schedule (₹49 Cr loss vs ₹236 Cr prior Q, strong volume growth). Cluster 2 (Lucknow/Patna) outperforming. However, Gurgaon growth deceleration and PAT flat despite revenue +26.5% suggests execution gaps on cost control.
1 · Q2 FY27
Noida aims for EBITDA breakeven; Gurgaon to activate 2 additional OTs (total 44-45)
2 · Q2 FY27, early Q3
Indore 80-bed acquisition and cancer services scaling commission
3 · H2 FY27
Guwahati construction ramp-up; South Delhi project progression
Long-term, the 3,350-bed expansion pipeline and Cluster 2's 32% margins are compelling, but execution risk on capex (Guwahati cost inflation) and near-term profitability headwinds warrant a cautious stance.
Medanta Q1: revenue +26% YoY, consolidated PAT flat at Rs157 Cr as Noida ramp squeezes margins
PAT -1.09% YoY · revenue +26.5% · margins compressing
₹1,304.05 Cr
+26.5% YoY
₹157.25 Cr
-1.09% YoY
11.86%
-3.3pp YoY
₹5.91
Global Health (Medanta) opened FY27 with strong volume-led growth but a flat bottom line on a reported basis. Consolidated revenue from operations rose 26.5% YoY to Rs1,304 Cr (+12.5% QoQ), yet consolidated PAT was Rs157.3 Cr, down 1.1% YoY and up 11% QoQ. The optics understate the underlying trend: the year-ago Q1FY26 profit carried a one-off Rs19.6 Cr EPCG interest-reversal gain, and stripping it out lifts adjusted PAT growth to ~+13% YoY — steady, but well behind the topline.
Q1 FY-2027 vs prior quarters
The gap between revenue and profit growth sits on the cost lines tied to the new-hospital ramp. Depreciation jumped ~53% YoY to Rs69 Cr and finance costs nearly doubled (+93%) to Rs26.7 Cr as the Noida facility and greenfield capex feed through — exactly the drag management flagged, having guided Noida to breakeven only in H2 FY27. Net margin fell to 12.1% (vs ~13.5% adjusted a year ago), and EBITDA margin eased to ~22.0% from 23.9% YoY, though it firmed sequentially from ~21% in Q4. So the print confirms rather than contradicts the last concall: strong revenue ramp, margins temporarily diluted by immature capacity, on an optimistic long-term stance.
The stock went into the print at ₹1,423, up 7.2% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management projects continued strong growth driven by the rapid ramp-up of the Noida facility, which is expected to reach breakeven in H2 FY27. The company plans to add approximately 500 beds across existing hospitals in the short-term and a further 2,700 beds through its funded greenfield pipeline over the next 3-4 ye
— This quarter: met
Against prior guidance the quarter is broadly on-track — management projected continued strong growth with FY27 capex of Rs800-900 Cr and phased bed additions, and this print delivers the growth while the margin dilution is the pre-breakeven Noida cost it had signalled; no formal quarterly PAT guidance is given. Standalone told a similar story (revenue Rs1,078.7 Cr, PAT Rs137.3 Cr). Concurrent board actions reinforce the expansion narrative: the Guwahati project was enlarged from 400 to 650 beds at ~Rs970 Cr over 3-4 years, existing capacity stands at 3,737 beds across six cities, a Chief Digital Officer was appointed, and a Rs0.50/share FY26 final dividend was set (record date Aug 14). We could not source a firm Street consensus for the quarter, so vs-street is left unknown rather than inferred.
W1
Noida facility breakeven guided for H2 FY27 — watch finance costs (Rs26.7 Cr/qtr) and depreciation (Rs69 Cr/qtr) converting to operating leverage
W2
FY27 capex guided at Rs800-900 Cr plus ~500 near-term bed additions and the Rs970 Cr Guwahati build — track balance-sheet/debt impact
W3
Margin recovery: EBITDA margin ~22% needs to rebuild toward the mature ~24% level as new units season
Clean digital filing, in Rs millions (converted to Cr). No exceptional item this quarter; year-ago Q1FY26 PAT included a +Rs19.6 Cr EPCG interest-reversal exceptional GAIN (bracketed but additive to PBT) — used for adjusted growth. Consolidated PAT Rs157.3 Cr total; owners' share Rs158.7 Cr, NCI -Rs1.5 Cr. Unaudited/limited review.